Anixa Biosciences (NASDAQ:ANIX) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Anixa Biosciences (NASDAQ:ANIX) issued its quarterly earnings results on Wednesday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03, FiscalAI reports.

Anixa Biosciences Price Performance

NASDAQ:ANIX opened at $2.35 on Thursday. The company’s 50-day moving average is $2.78 and its two-hundred day moving average is $3.12. Anixa Biosciences has a 1-year low of $2.35 and a 1-year high of $5.46. The firm has a market capitalization of $78.80 million, a price-to-earnings ratio of -7.12 and a beta of 0.59.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in Anixa Biosciences in the fourth quarter valued at $161,000. Millennium Management LLC acquired a new stake in shares of Anixa Biosciences in the fourth quarter valued at $38,000. 683 Capital Management LLC purchased a new position in Anixa Biosciences in the fourth quarter valued at $355,000. Cetera Investment Advisers purchased a new position in Anixa Biosciences in the fourth quarter valued at $35,000. Finally, ExodusPoint Capital Management LP acquired a new position in Anixa Biosciences during the 4th quarter worth $293,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on ANIX shares. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research report on Wednesday, April 8th. Wall Street Zen downgraded shares of Anixa Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Anixa Biosciences has an average rating of “Hold” and an average price target of $8.50.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.